Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine  model of chronic lymphocytic leukemia.

Antigens, CD; Neoplasm Proteins; Pdcd1 protein, mouse; Programmed Cell Death 1 Receptor; Lymphocyte Activation Gene 3 Protein; Animals; Antigens, CD/genetics/metabolism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell/genetics/metabolism; Mice; Neoplasm Proteins/genetics/metabolism; Neoplasms, Experimental/genetics/metabolism; Programmed Cell Death 1 Receptor/genetics/metabolism

Disciplines :

Oncology

Author, co-author :

Wierz, Marina ; Laboratory of Experimental Cancer Research, Department of Oncology.

Pierson, Sandrine; Laboratory of Experimental Cancer Research, Department of Oncology.

Guyonnet, Léa; Department of Infection and Immunity. ; National Cytometry Platform, Department of Infection and Immunity, and.

VIRY, Elodie ; Laboratory of Experimental Cancer Research, Department of Oncology.

Lequeux, Audrey; Laboratory of Experimental Cancer Research, Department of Oncology.

Oudin, Anaïs; NorLux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.

NICLOU, Simone P. ; NorLux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.

OLLERT, Markus ; Department of Infection and Immunity. ; Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, University of Southern Denmark, Odense, Denmark,

BERCHEM, Guy Joseph Maximilien Jean ; Laboratory of Experimental Cancer Research, Department of Oncology. ; Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.

JANJI, Bassam ; Laboratory of Experimental Cancer Research, Department of Oncology.

More authors (3 more)

External co-authors :

yes

Language :

English

Title :

Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.

Publication date :

05 April 2018

Journal title :

Blood

ISSN :

0006-4971

eISSN :

1528-0020

Publisher :

American Society of Hematology, Washington, United States - District of Columbia

Volume :

131

Issue :

Pages :

1617-1621

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBilu :

since 27 February 2024

Statistics

Number of views

5 (1 by Unilu)

Number of downloads

1 (0 by Unilu)

More statistics

Scopus citations^®

104

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-3375.
Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol. 2009;27(2):129-139.
Cutucache CE. Tumor-induced host immunosuppression: special focus on CLL. Int Immunopharmacol. 2013;17(1):35-41.
Curran EK, Godfrey J, Kline J. Mechanisms of immune tolerance in leukemia and lymphoma. Trends Immunol. 2017;38(7):513-525.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33(17):1974-1982.
Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120(7):1412-1421.
McClanahan F, Riches JC, Miller S, et al. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Em-TCL1 CLL mouse model. Blood. 2015;126(2):212-221.
McClanahan F, Hanna B, Miller S, et al. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood. 2015;126(2):203-211.
Cheng G, Yuan X, Tsai MS, Podack ER, Yu A, Malek TR. IL-2 receptor signaling is essential for the development of Klrg11 terminally differentiated T regulatory cells. J Immunol. 2012;189(4):1780-1791.
Cibrián D, Sánchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017;47(6):946-953.
Zelenay S, Lopes-Carvalho T, Caramalho I, Moraes-Fontes MF, Rebelo M, Demengeot J. Foxp31 CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci USA. 2005;102(11): 4091-4096.
Okamura T, Sumitomo S, Morita K, et al. TGF-b3-expressing CD41CD25(-)LAG31 regulatory T cells control humoral immune responses. Nat Commun. 2015;6(1):6329.
Asano T, Meguri Y, Yoshioka T, et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017;129(15): 2186-2197.
Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp31 regulatory T cell function. Science. 2008;322(5899):271-275.
Kronin V, Fitzmaurice CJ, Caminschi I, Shortman K, Jackson DC, Brown LE. Differential effect of CD8(1) and CD8(-) dendritic cells in the stimulation of secondary CD4(1) T cells. Int Immunol. 2001;13(4):465-473.
Yamazaki S, Dudziak D, Heidkamp GF, et al. CD81 CD2051 splenic dendritic cells are specialized to induce Foxp31 regulatory T cells. J Immunol. 2008;181(10):6923-6933.
Hanna BS, McClanahan F, Yazdanparast H, et al. Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia. 2016; 30(3):570-579.
Elias CG III, Spellberg JP, Karan-Tamir B, et al. Ligation of CD31/PECAM-1 modulates the function of lymphocytes, monocytes and neutrophils. Eur J Immunol. 1998;28(6):1948-1958.